{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T19:06:22Z","timestamp":1772046382787,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.gim.2022.04.002","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:26:13Z","timestamp":1653006373000},"page":"1437-1448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-term open-label phase I\/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4035-6592","authenticated-orcid":false,"given":"Joseph","family":"Muenzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Vijayaraghavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margot","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shauna","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuna","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Alexanderian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gim.2022.04.002_bib1","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"issue":"4","key":"10.1016\/j.gim.2022.04.002_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","article-title":"The natural history of the severe form of Hunter\u2019s syndrome: a study based on 52 cases","volume":"25","author":"Young","year":"1983","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"10.1016\/j.gim.2022.04.002_bib3","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/jmg.19.6.408","article-title":"A\u00a0clinical and genetic study of Hunter\u2019s syndrome. 2. Differences between the mild and severe forms","volume":"19","author":"Young","year":"1982","journal-title":"J\u00a0Med Genet"},{"issue":"11","key":"10.1016\/j.gim.2022.04.002_bib4","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/adc.57.11.828","article-title":"Mild form of Hunter\u2019s syndrome: clinical delineation based on 31 cases","volume":"57","author":"Young","year":"1982","journal-title":"Arch Dis Child"},{"issue":"7","key":"10.1016\/j.gim.2022.04.002_bib5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","article-title":"Initial report from the Hunter Outcome Survey","volume":"10","author":"Wraith","year":"2008","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.gim.2022.04.002_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur J Pediatr"},{"issue":"4","key":"10.1016\/j.gim.2022.04.002_bib7","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","article-title":"Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS)","volume":"32","author":"Jones","year":"2009","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"Suppl 1","key":"10.1016\/j.gim.2022.04.002_bib8","first-page":"107","article-title":"Mucopolysaccharidosis type II, Hunter\u2019s syndrome","volume":"12","author":"Tylki-Szyma\u0144ska","year":"2014","journal-title":"Pediatr Endocrinol Rev"},{"issue":"6","key":"10.1016\/j.gim.2022.04.002_bib9","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10545-017-0075-x","article-title":"Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS)","volume":"40","author":"Burton","year":"2017","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"8","key":"10.1016\/j.gim.2022.04.002_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A\u00a0phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.gim.2022.04.002_bib11","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S139601","article-title":"Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future","volume":"11","author":"Whiteman","year":"2017","journal-title":"Drug Des Dev Ther"},{"issue":"3","key":"10.1016\/j.gim.2022.04.002_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A\u00a0phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.gim.2022.04.002_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.gim.2022.04.002_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/GIM.0b013e318206786f","article-title":"Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.gim.2022.04.002_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1590\/S1415-47572014000300003","article-title":"Guidelines for diagnosis and treatment of Hunter syndrome for clinicians in Latin America","volume":"37","author":"Giugliani","year":"2014","journal-title":"Genet Mol Biol"},{"issue":"1","key":"10.1016\/j.gim.2022.04.002_bib16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13023-017-0712-3","article-title":"Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the Hunter Outcome Survey (HOS)","volume":"12","author":"Muenzer","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.gim.2022.04.002_bib17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2019.07.016","article-title":"Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England","volume":"129","author":"Broomfield","year":"2020","journal-title":"Mol Genet Metab"},{"issue":"16","key":"10.1016\/j.gim.2022.04.002_bib18","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2174\/138161208784705504","article-title":"Lysosomal storage diseases and the blood\u2013brain barrier","volume":"14","author":"Begley","year":"2008","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.gim.2022.04.002_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00431-011-1606-3","article-title":"The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus","volume":"171","author":"Muenzer","year":"2012","journal-title":"Eur J Pediatr"},{"issue":"2","key":"10.1016\/j.gim.2022.04.002_bib20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A\u00a0phase 2\/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.gim.2022.04.002_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.omtm.2021.02.018","article-title":"Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II","volume":"21","author":"Seo","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.gim.2022.04.002_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A\u00a0phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.gim.2022.04.002_bib23","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1177\/0192623311409595","article-title":"Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys","volume":"39","author":"Felice","year":"2011","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.gim.2022.04.002_bib24","series-title":"Differential Ability Scales: Introductory and Technical Handbook","author":"Elliott","year":"2007"},{"issue":"2","key":"10.1016\/j.gim.2022.04.002_bib25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/1073191119872250","article-title":"Projected Retained Ability Score (PRAS): A new methodology for quantifying absolute change in norm-based psychological test scores over time","volume":"28","author":"Kronenberger","year":"2021","journal-title":"Assessment"},{"key":"10.1016\/j.gim.2022.04.002_bib26","series-title":"Bayley Scales of Infant and Toddler Development\u2014Third Edition: Technical manual","author":"Bayley","year":"2006"},{"issue":"1-2","key":"10.1016\/j.gim.2022.04.002_bib27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ymgme.2018.07.013","article-title":"Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC\/MS\/MS","volume":"125","author":"Tanaka","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.gim.2022.04.002_bib28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","article-title":"The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase","volume":"110","author":"Barbier","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.gim.2022.04.002_bib30","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fimmu.2020.01000","article-title":"Immune modulation for enzyme replacement therapy in a female patient with Hunter syndrome","volume":"11","author":"Julien","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.gim.2022.04.002_bib31","first-page":"20","article-title":"Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II","volume":"2","author":"Kim","year":"2014","journal-title":"Mol Genet Metab Rep"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360022007195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360022007195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:52:35Z","timestamp":1761097955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360022007195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1098360022007195"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2022.04.002","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term open-label phase I\/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2022.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.","name":"copyright","label":"Copyright"}]}}